Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary - About
Cybin Inc (CYBN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: CYBN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -55.59% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 196.09M USD | Price to earnings Ratio - | 1Y Target Price 90.76 |
Price to earnings Ratio - | 1Y Target Price 90.76 | ||
Volume (30-day avg) 296089 | Beta 0.94 | 52 Weeks Range 6.50 - 19.84 | Updated Date 02/21/2025 |
52 Weeks Range 6.50 - 19.84 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.5 |
Earnings Date
Report Date 2025-02-11 | When - | Estimate -1.5675 | Actual -0.53 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -44.06% | Return on Equity (TTM) -57.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 87670382 | Price to Sales(TTM) 278.25 |
Enterprise Value 87670382 | Price to Sales(TTM) 278.25 | ||
Enterprise Value to Revenue 313.59 | Enterprise Value to EBITDA -3.79 | Shares Outstanding 21016900 | Shares Floating 18315557 |
Shares Outstanding 21016900 | Shares Floating 18315557 | ||
Percent Insiders - | Percent Institutions 42.13 |
AI Summary
Company Profile:
Cybin Inc. is a biopharmaceutical company focused on developing cutting-edge psychedelic pharmaceutical products to provide innovative therapies for mental health disorders. The company was founded in 2019 and is headquartered in Toronto, Canada. Cybin Inc. is dedicated to advancing the field of psychedelic medicine through research, development, and commercialization of novel therapies.
The core business areas of Cybin Inc. include research and development of psychedelic compounds for the treatment of various mental health disorders such as depression, anxiety, and PTSD. The company is also involved in clinical trials to evaluate the safety and efficacy of its products and is working towards obtaining regulatory approvals for commercialization.
The leadership team of Cybin Inc. is comprised of experienced professionals with expertise in drug development, clinical research, and business management. The corporate structure of the company includes key departments such as research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share:
Cybin Inc.'s top products include novel psychedelic compounds for the treatment of mental health disorders. These products are in the early stages of development and are currently being evaluated in clinical trials. The market share of these products in the global and US markets is not applicable at this time as they are still in the research and development phase.
Financial Performance:
As a relatively new company, Cybin Inc. does not have a long history of financial performance. However, recent financial statements show promising growth potential with a focus on research and development activities. The company's revenue, net income, profit margins, and earnings per share (EPS) are not publicly disclosed at this time.
Dividends and Shareholder Returns:
Cybin Inc. does not currently pay dividends as it is focused on reinvesting its profits into research and development activities. Shareholder returns are dependent on the company's growth trajectory and market performance.
Growth Trajectory:
Cybin Inc. has shown a strong growth trajectory in recent years with a focus on developing innovative psychedelic therapies for mental health disorders. The company has made significant progress in research and development and is poised for future growth based on industry trends and market demand.
Market Dynamics:
Cybin Inc. operates in the emerging field of psychedelic medicine, which is experiencing rapid growth and increasing acceptance in the medical community. The company is well positioned to capitalize on this trend through its innovative product offerings and research initiatives.
Competitors:
Key competitors of Cybin Inc. in the psychedelic medicine space include MindMed Inc. (MMED) and Compass Pathways (CMPS). Cybin Inc. faces competition in the development of psychedelic therapies, but differentiates itself through its unique product offerings and research focus.
Potential Challenges and Opportunities:
Key challenges facing Cybin Inc. include regulatory hurdles, market competition, and funding for research and development. However, the company also has opportunities for growth through new market expansion, product innovations, and strategic partnerships.
Recent Acquisitions (Last 3 Years):
There are no recent acquisitions by Cybin Inc. in the last 3 years.
AI-Based Fundamental Rating:
Based on an AI-based rating system, Cybin Inc. receives a score of 8 out of 10. This rating is justified by the company's strong focus on research and development, innovative product offerings, and growth potential in the emerging psychedelic medicine market.
Sources and Disclaimers:
Sources used for this analysis include company reports, financial statements, industry publications, and market research data. This information is for informational purposes only and should not be considered as investment advice. Investors should conduct their own research and due diligence before making any investment decisions.
About Cybin Inc
Exchange NYSE MKT | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2019-09-13 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 50 | Website https://www.cybin.com |
Full time employees 50 | Website https://www.cybin.com | ||
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. It also has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.